1. Home
  2. GPRK vs IMMP Comparison

GPRK vs IMMP Comparison

Compare GPRK & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Geopark Ltd

GPRK

Geopark Ltd

HOLD

Current Price

$9.29

Market Cap

608.0M

Sector

Energy

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.58

Market Cap

58.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GPRK
IMMP
Founded
2002
1987
Country
Colombia
Australia
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
608.0M
58.2M
IPO Year
2009
2012

Fundamental Metrics

Financial Performance
Metric
GPRK
IMMP
Price
$9.29
$0.58
Analyst Decision
Hold
Hold
Analyst Count
1
3
Target Price
$8.50
$5.50
AVG Volume (30 Days)
1.4M
19.6M
Earning Date
05-06-2026
04-23-2026
Dividend Yield
1.31%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$39.45
$417.85
Revenue Next Year
N/A
N/A
P/E Ratio
$12.70
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.75
$0.29
52 Week High
$10.34
$3.53

Technical Indicators

Market Signals
Indicator
GPRK
IMMP
Relative Strength Index (RSI) 52.19 37.52
Support Level $7.87 N/A
Resistance Level $10.16 $1.75
Average True Range (ATR) 0.55 0.06
MACD 0.01 0.11
Stochastic Oscillator 58.50 37.80

Price Performance

Historical Comparison
GPRK
IMMP

About GPRK Geopark Ltd

GeoPark Ltd is an independent energy company. Its diversified portfolio of assets consist of Llanos 34 Block in Colombia, CPO-5 Block, Llanos 86, Llanos 87, Llanos 104, Llanos 123, and Llanos 124 Blocks in the Llanos Basin. Its segments include Colombia, Argentina, Brazil and Ecuador, with the majority of the revenue derived from Colombia. It derives revenue from Sale of crude oil, Sale of purchased crude oil, and Sale of gas.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: